• Profile

Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: A meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database

Osteoporosis International Feb 11, 2022

Findings support cardiovascular safety of alendronate as a first-line choice for osteoporosis treatment.

  • In this propensity-matched cohort study and meta-analysis, patients were taken from the SIDIAP or CPRD database to assess the risk of acute myocardial infarction in patients taking osteoporosis medication.

  • Relative to alendronate users, a 10% elevated risk of acute myocardial infarction was found in users of other bisphosphonates within CPRD.

  • A 9% elevated risk in users of other bisphosphonate vs alendronate users was shown by the findings of meta-analysis of CPRD and SIDIAP.

  • In the sensitivity analysis, an increased risk was found in selective oestrogen receptor modulators users with diabetes and chronic kidney disease.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen